- Home
- CHI vs ENOV Comparison
CHI vs ENOV Comparison
Compare CHI & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | ENOV |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | 7802 |
| Industry | Investment Managers | Fluid Controls |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2002 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CHI | ENOV |
|---|---|---|
| Price | $11.98 | $17.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $37.58 |
| AVG Volume (30 Days) | 193.1K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.05 |
| Revenue Next Year | N/A | $4.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.26 | $16.70 |
| 52 Week High | $13.50 | $34.28 |
Technical Indicators
Market Signals| Indicator | CHI | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 38.65 |
| Support Level | $11.93 | $17.30 |
| Resistance Level | $12.13 | $18.79 |
| Average True Range (ATR) | 0.28 | 0.76 |
| MACD | 0.05 | 0.20 |
| Stochastic Oscillator | 59.35 | 43.72 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About ENOV Enovis Corporation
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.